US Patent 4,966,891 covered a broad class of 5'-deoxy-5-fluorocytidine prodrugs, including N4-acyl, N4-carbamate, N4-thiocarbamate and selected sugar-hydroxyl-protected derivatives. Its central commercial concept was conversion of 5'-deoxy-5-fluorocytidine, commonly known as doxifluridine or 5'-DFUR, into orally administered derivatives designed to release 5-fluorouracil or related active metabolites under physiological conditions. The patent issued on October 30, 1990, and its ordinary 17-year United States term expired on October 30, 2007. It is therefore not an active United States exclusion right.

United States Drug Patent 4,966,891: Claims, Scope and Patent Landscape

What does United States Patent 4,966,891 cover?

US 4,966,891 covers substituted derivatives of 5'-deoxy-5-fluorocytidine in which one or more substituents are physiologically hydrolyzable. The patent also covers hydrates and solvates of the claimed compounds.

The claimed invention has four principal layers:

A broad chemical genus covering derivatives with up to three hydrolyzable substituents.
Defined acyl, carbamate and thiocarbamate substituents.
Long lists of expressly named chemical species.
Therapeutic compositions, antitumor methods and manufacturing processes.

The patent is assigned to F. Hoffmann-La Roche AG and is directed to fluoropyrimidine prodrug chemistry. Its technical objective was to modify the polarity, absorption, distribution or metabolic conversion of 5'-deoxy-5-fluorocytidine.

What chemical scaffold does US 4,966,891 claim?

The core scaffold is 5'-deoxy-5-fluorocytidine. The claim language identifies three independently variable positions, represented by R1, R2 and R3 in the structural formula reproduced in the patent. Each position may be hydrogen or an easily hydrolyzable radical, provided that at least one position contains such a radical.

The issued claims and listed species indicate that the relevant substitution sites include:

The exocyclic N4-amino group of the cytosine base.
One or more ribose hydroxyl groups, including 2'-O and 3'-O positions.
Combinations of N4 substitution and sugar hydroxyl protection.

The claim set is therefore broader than a single molecule. It covers a family of masked fluorocytidine compounds whose substituents can be removed by hydrolysis or enzymatic metabolism.

What does “easily hydrolyzable radical” mean in the patent?

Claim 2 defines the term through three principal classes:

Radical class	General structure	Commercial or technical function
Acyl	R4CO-	Masks an amino or hydroxyl group and can hydrolyze to the parent functionality
Carbamate	R5OCO-	Forms an ester-like or carbamate prodrug substituent
Thiocarbamate	R6SCO-	Provides a sulfur-containing hydrolyzable derivative

The R4 group may be hydrogen, alkyl, cycloalkyl, oxoalkyl, alkenyl, aralkyl or aryl. The R5 and R6 groups may be alkyl or aralkyl.

This language creates a broad genus, but the practical scope depends on whether a particular substituent is sufficiently labile under physiological conditions. A chemically stable derivative may fall outside the intended claim even if its structure resembles an expressly listed compound.

Which compounds are expressly listed in the claims?

Claim 3 lists numerous N4-acyl derivatives of 5'-deoxy-5-fluorocytidine. Examples include:

N4-acetyl-5'-deoxy-5-fluorocytidine.
N4-propionyl, butyryl, isobutyryl and pivaloyl derivatives.
Valeryl, isovaleryl, hexanoyl, heptanoyl, octanoyl and hexadecanoyl derivatives.
N4-benzoyl and substituted benzoyl derivatives.
Methoxy, ethoxy, propoxy, chloro, nitro and methyl-substituted benzoyl derivatives.
N4-nicotinoyl, isonicotinoyl and picolinoyl derivatives.
Furoyl, nitrofuroyl and thenoyl derivatives.
Phenylacetyl and substituted phenylacetyl derivatives.
N4-(3-butenoyl) derivatives.
3'-O-benzoyl derivatives.
N4,3'-O-dibenzoyl derivatives.
N4-(ethylthio)carbonyl derivatives.

Claim 4 adds further species, including:

N4-octadecanoyl derivatives.
Cyclopropanecarbonyl, cyclohexanecarbonyl and adamantanecarbonyl derivatives.
Additional methoxy, fluoro, chloro, nitro, methylthio and naphthoyl benzoyl compounds.
Furoyl and phenylpropionyl derivatives.
N4-cinnamoyl derivatives.
2',3'-di-O-benzoyl and N4,2'-O,3'-O-tribenzoyl derivatives.
N4-octyloxycarbonyl derivatives.
N4-benzyloxycarbonyl derivatives.
N4-formyl derivatives.

The species claims have two consequences. First, they provide fallback positions if a court limits the broad genus in claim 1. Second, they establish that the patent was intended to cover multiple prodrug designs rather than only one preferred compound.

Does US 4,966,891 claim capecitabine?

US 4,966,891 should not be treated as the principal patent on capecitabine.

Capecitabine is 5'-deoxy-5-fluoro-N4-pentyloxycarbonylcytidine. The later capecitabine patent, US 5,472,949, specifically claims the pentyloxycarbonyl derivative and related therapeutic uses. Capecitabine was developed and commercialized as Xeloda by Hoffmann-La Roche. US 5,472,949 issued on December 5, 1995, and its ordinary patent term expired in December 2013, subject to any applicable patent-term adjustment or extension.

The earlier patent is relevant because it discloses and claims the broader concept of hydrolyzable substitution on 5'-deoxy-5-fluorocytidine. The later patent is more important for capecitabine-specific validity, infringement and generic-entry analysis.

Issue	US 4,966,891	US 5,472,949
Core subject	Broad hydrolyzable 5'-deoxy-5-fluorocytidine derivatives	Capecitabine and related N4-carbamate compounds
Key substituents	Acyl, carbamate, thiocarbamate and protected sugar groups	N4-pentyloxycarbonyl and related compounds
Commercial product	No current US product directly depends on the patent	Xeloda, capecitabine
Issue date	October 30, 1990	December 5, 1995
Ordinary term expiration	October 30, 2007	December 2013
Current status	Expired	Expired

How broad is claim 1 of US 4,966,891?

Claim 1 is a composition-of-matter claim with a functional limitation. It requires:

The disclosed 5'-deoxy-5-fluorocytidine nucleus.
Three variable positions represented by R1, R2 and R3.
Each variable position being hydrogen or an easily hydrolyzable radical.
At least one radical being hydrolyzable under physiological conditions.
Hydrates and solvates of the claimed compounds.

The claim does not require a particular dose, formulation, disease, route of administration or degree of antitumor activity. A qualifying compound could therefore infringe based on its chemical structure alone, regardless of whether it is sold as a tablet, capsule, injectable product or research intermediate.

The principal limitations are the identity of the fluorocytidine scaffold and the hydrolyzability requirement. The phrase “under physiological conditions” may require analysis of aqueous stability, pH dependence, enzymatic conversion and the relevant biological environment.

How strong is the composition-of-matter claim?

Historically, claim 1 had meaningful breadth because it covered a large number of substituent combinations. Its strength was reduced by several factors:

The claim relies on the potentially fact-intensive term “easily hydrolyzable.”
The specification appears to emphasize particular substituent classes and examples.
The field already contained extensive fluoropyrimidine and fluorocytidine prodrug research.
A later compound-specific patent could provide a more focused and commercially useful claim position.
The patent expired before modern commercial capecitabine litigation became the principal issue.

For present-day freedom-to-operate analysis, legal strength is secondary to status. An expired composition claim cannot block manufacture, sale or use in the United States.

What does claim 5 cover?

Claim 5 is a method-of-treatment claim covering inhibition of the growth of:

Sarcoma.
Fibrosarcoma.
Carcinoma.

The method requires administering an antitumor-effective amount of a compound of Formula I, or a hydrate or solvate.

The claim is narrower than claim 1 in subject matter but broad in therapeutic implementation. It does not specify:

A particular tumor subtype.
A treatment schedule.
A dose.
A route of administration.
A formulation.
A biomarker.
A requirement that the compound be converted to 5-fluorouracil in vivo.

The method claim would have been relevant to clinical use during the patent term. It does not create a current US barrier because the patent has expired.

What does claim 6 cover?

Claim 6 is a manufacturing-process claim. It covers reacting a protected 5'-deoxy-5-fluorocytidine intermediate with an acylating or carbonylating reagent, followed where necessary by removal of protecting groups.

The process includes:

An amino-protected or unprotected cytidine intermediate.
Hydroxyl groups that may be individually protected.
A cyclic protecting group covering two hydroxyl groups.
Acylation using a compound of formula XCOR4, where X is a leaving group.
Carbamoylation or thiocarbamoylation using a compound of formula YCOR10, where Y is halogen.
Deprotection to produce the final prodrug.

This process claim is narrower than a general claim to any manufacturing route. A process that uses a different reaction sequence, different activating reagent or different protecting-group strategy may fall outside claim 6 even if it produces a compound covered by claim 1.

Because claim 6 expired in 2007, it does not currently restrict US manufacturing.

What does claim 7 cover?

Claim 7 covers pharmaceutical compositions containing a therapeutically effective amount of a Formula I compound with antisarcoma, antifibrosarcoma or anticarcinoma activity.

The claim does not recite a particular excipient, dosage form or delivery system. It could historically have reached conventional oral or parenteral compositions containing a claimed compound. It does not specifically claim:

Enteric coating.
Sustained release.
Nanoparticles.
Liposomes.
Specific tablet excipients.
A fixed-dose combination.
A particular particle size or polymorph.

No formulation-specific protection should be inferred from claim 7. The claim is a composition claim defined mainly by the active ingredient and therapeutic activity.

When did US Patent 4,966,891 lose exclusivity?

The patent issued on October 30, 1990. For a pre-1995 US application, the ordinary term was generally 17 years from grant. On that basis, the patent expired on October 30, 2007, absent a term adjustment or other special extension.

Milestone	Date or status
US patent	4,966,891
Issue date	October 30, 1990
Ordinary term rule	17 years from issue
Ordinary expiration	October 30, 2007
Current status	Expired
Current enforceability	None after expiration

The patent cannot support a new Paragraph IV lawsuit, injunction or damages claim for conduct occurring after expiration. Earlier conduct would require a separate historical infringement and limitations analysis.

What is the Orange Book status of US 4,966,891?

US 4,966,891 is not the operative Orange Book patent for current capecitabine products. Orange Book listing is tied to approved drug products and patents that claim the drug, its formulation or an approved method of use. The principal historical capecitabine patent position centered on later capecitabine-specific patents, including US 5,472,949, rather than on the expired 1990 patent.

FDA’s Orange Book and Xeloda labeling should be reviewed separately from the broader historical patent family. A patent can be technically relevant to a drug’s development history without being listed against the approved NDA.

Were there Paragraph IV challenges involving this patent?

US 4,966,891 was not the principal Paragraph IV target for capecitabine generic entry because it expired in 2007. Paragraph IV disputes concerning capecitabine focused on later, product-specific patents associated with Xeloda and its approved uses.

The commercial significance of the 4,966,891 patent was therefore prior-art and historical patent-estate significance, not current ANDA litigation leverage. After expiration, an ANDA applicant no longer has to defeat this patent to launch a product.

What patent litigation affects the 4,966,891 patent?

The patent’s expiration materially limits current litigation relevance. No active US enforcement right remains under the patent.

Historical disputes involving fluoropyrimidine prodrugs were more likely to focus on:

Later capecitabine compound patents.
Formulation or dosage patents.
Method-of-use claims.
Patent-term calculations.
Generic applicants’ Paragraph IV certifications.
Noninfringement and invalidity defenses based on the scope of later patents.

The 4,966,891 patent may still appear in invalidity searches, prosecution histories, freedom-to-operate opinions or prior-art analyses. It cannot independently delay a US generic launch today.

What formulation patents are relevant to this estate?

The issued claims of US 4,966,891 do not provide meaningful formulation specificity. They cover compounds, treatment methods and a manufacturing route. They do not identify a protected commercial tablet architecture or a specific excipient system.

For capecitabine, later patent analysis should separate:

Patent category	Relevance
Compound patents	Protect capecitabine or related N4-carbamates
Method-of-use patents	Cover treatment of specified cancers or dosing regimens
Formulation patents	Cover tablets, stability systems, release profiles or combinations
Process patents	Cover synthesis, purification or crystallization
Regulatory exclusivity	Operates independently of patent claims

The original compound patent should not be assumed to cover every later formulation or manufacturing improvement.

What manufacturing and intellectual-property barriers existed?

During the patent term, the main barriers were chemistry and regulatory approval, not merely possession of the active ingredient. Relevant technical issues included:

Selective N4 acylation or carbamoylation.
Protection and deprotection of the 2' and 3' hydroxyl groups.
Control of regioisomers and over-acylated byproducts.
Removal of residual protecting-group reagents.
Solid-state and solvate control.
Stability during storage and formulation.
Demonstration of reproducible conversion to active fluoropyrimidine metabolites.

These barriers could support separate process or quality patents, but they do not extend the term of US 4,966,891.

How does the patent estate compare with competing fluoropyrimidines?

Product or compound	Relationship to US 4,966,891	Current US patent position
5-Fluorouracil	Active metabolite or pharmacologic comparator	Original patents expired
5'-DFUR / doxifluridine	Parent fluorocytidine prodrug scaffold	Historical patent protection expired
Capecitabine	Later N4-pentyloxycarbonyl derivative	Principal US patents expired
Tegafur	Different 5-fluorouracil prodrug	Historical patents expired
UFT	Tegafur/uracil combination	Historical patent and regulatory issues differ
S-1	Tegafur-based combination	Combination-specific estate differs

US 4,966,891 is best understood as an early platform patent around hydrolyzable 5'-deoxy-5-fluorocytidine derivatives. It is not the complete patent estate for capecitabine, tegafur or other fluoropyrimidine products.

What generic launch risks remain?

For the specific 4,966,891 patent, the US generic-launch risk is zero because the patent expired in 2007. For capecitabine products, the relevant historical risk came from later capecitabine patents and any remaining regulatory exclusivity.

A current manufacturer should distinguish among:

Direct manufacture of a claimed historical compound.
Manufacture of capecitabine.
Use in an FDA-approved cancer indication.
A particular dosage regimen.
A specific formulation.
A manufacturing process or polymorph.

The expired 4,966,891 patent does not prevent any of these activities in the United States.

What is the geographic coverage of the patent family?

US 4,966,891 provides territorial rights only in the United States. Foreign counterparts, if granted, had separate terms, claim scopes and legal outcomes. A US expiration date cannot be applied automatically to Europe, Japan, Canada or other jurisdictions.

For multinational diligence, the relevant questions are:

Whether a corresponding national patent issued.
Whether the foreign patent was maintained.
Whether patent-term restoration or supplementary protection applied.
Whether a local capecitabine or fluorocytidine patent had a later expiration.
Whether local regulatory exclusivity delayed generic approval.

The US patent’s expired status does not establish freedom to operate in other countries.

Key Takeaways

US 4,966,891 covers hydrolyzable derivatives of 5'-deoxy-5-fluorocytidine.
Its claims include N4-acyl, N4-carbamate, N4-thiocarbamate and selected O-protected compounds.
Claim 1 is a broad chemical genus; claims 3 and 4 list numerous specific species.
Claim 5 covers treatment of sarcoma, fibrosarcoma and carcinoma.
Claim 6 covers selected protected-intermediate acylation and carbonylation processes.
Claim 7 covers pharmaceutical compositions containing Formula I compounds.
The patent issued October 30, 1990, and its ordinary term expired October 30, 2007.
It is not the principal current Orange Book barrier for capecitabine.
Capecitabine was protected primarily by later patents, including US 5,472,949.
No current US generic-launch barrier arises from US 4,966,891.

FAQs about US Patent 4,966,891

Is US 4,966,891 still enforceable?

No. The patent’s ordinary US term expired on October 30, 2007.

Does US 4,966,891 cover Xeloda?

It covers a broad class of related fluorocytidine prodrugs, but the principal capecitabine patent was the later US 5,472,949 patent.

Does the patent cover 5-fluorouracil itself?

No. The claims are directed to substituted 5'-deoxy-5-fluorocytidine derivatives, not to unmodified 5-fluorouracil.

Can a company manufacture an N4-acyl fluorocytidine in the United States?

US 4,966,891 no longer prevents manufacture because its claims have expired. Separate active patents, regulatory requirements and product-specific rights must be assessed independently.

Is capecitabine a biologic or biosimilar product?

No. Capecitabine is a chemically synthesized small-molecule drug. Generic versions proceed through the ANDA pathway, not the biosimilar pathway.

References

F. Hoffmann-La Roche AG. (1990). N4-substituted-5'-deoxy-5-fluorocytidine derivatives and process for their preparation (U.S. Patent No. 4,966,891). United States Patent and Trademark Office.
F. Hoffmann-La Roche AG. (1995). 5'-Deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine (U.S. Patent No. 5,472,949). United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Xeloda (capecitabine) prescribing information. FDA.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term information. USPTO.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	87116926.4	Nov 17, 1987

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0316704	⤷ Start Trial	SPC/GB01/015	United Kingdom	⤷ Start Trial
European Patent Office	0316704	⤷ Start Trial	C300045	Netherlands	⤷ Start Trial
European Patent Office	0316704	⤷ Start Trial	2001C/021	Belgium	⤷ Start Trial
European Patent Office	0316704	⤷ Start Trial	14/2001	Austria	⤷ Start Trial
Argentina	247217	⤷ Start Trial
Austria	124951	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,966,891

Summary for Patent: 4,966,891